Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human beta-defensin 2
- Development stage
- Unknown
- Lead developer
- PLANTON
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
Recombinant human beta-defensin 2 (rHuβD2) is a topical biologic therapeutic developed by Planton GmbH for the treatment of skin infections in patients with atopic dermatitis (AD). As a recombinant form of the endogenous human host-defense peptide HBD2 (encoded by the DEFB4A gene), it aims to compensate for the defective induction of HBD2 typically seen in AD skin lesions. The peptide exerts its therapeutic effect by inhibiting Staphylococcus aureus-secreted extracellular proteases, such as V8 (SspA), thereby protecting the skin barrier from degradation. Additionally, it possesses broad antimicrobial properties against bacteria, fungi, and viruses through membrane permeabilisation. It is currently being evaluated in Phase I clinical trials as a topical cream.
- Other names
- human beta-defensin 2HBD2HBD-2HBD 2beta-defensin 2beta-defensin2beta-defensin-2DEFB4ADEFB-4ADEFB 4A
02
Targets
SspA (Glutamyl endopeptidase (Staphylococcus aureus V8))Gag (HIV-1 Gag polyprotein)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on recombinant human beta-defensin 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human beta-defensin 2.